Join to View Full Profile
460 W 10th AveColumbus, OH 43210
Phone+1 614-293-6529
Fax+1 614-293-9469
Dr. Shah is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 1997 - 1998
University at BuffaloFellowship, Hematology and Medical Oncology, 1995 - 1997- University at BuffaloResidency, Internal Medicine, 1992 - 1995
N.H.L Municipal Medical CollegeClass of 1990
Certifications & Licensure
OH State Medical License 1997 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Start of enrollment: 2001 Apr 01
- Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer Start of enrollment: 2003 Jan 01
- Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Start of enrollment: 2004 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Response to Letter to the Editor From Zhang et al: "Cabozantinib Plus Ipilimumab/Nivolumab in Patients with Previously Treated Advanced Differentiated Thyroid Cancer".Bhavana Konda, Eric J Sherman, Erminia Massarelli, Jorge Nieva, Jameel Muzaffar
The Journal of Clinical Endocrinology and Metabolism. 2025-06-17 - 3 citationsCabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer.Bhavana Konda, Eric J Sherman, Erminia Massarelli, Jorge Nieva, Jameel Muzaffar
The Journal of Clinical Endocrinology and Metabolism. 2025-02-18 - 12 citationsTelomere-lengthening germline variants predispose to a syndromic papillary thyroid cancer subtype.Emily A DeBoy, Anna M Nicosia, Sandya Liyanarachchi, Sheila S Iyer, Manisha H Shah
American Journal of Human Genetics. 2024-06-06
Journal Articles
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersLori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine
- Prognostic Impact of Serum Pancreastatin Following Chemoembolization for Neuroendocrine TumorsNeil Saunders, David Strosberg, Jill Onesti, Carl R Schmidt, Manisha Shah, Mary Dillhoff, Lawrence A Shirley, Bhavana Konda, Annals of Surgical Oncology
Authored Content
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung CancerAugust 2020
- Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
- Join now to see all
Press Mentions
Cabozantinib Active as Salvage Therapy in Thyroid CancerSeptember 5th, 2017
Targeted Therapies Show Initial Effectiveness in Subset of Papillary Thyroid CancerJune 5th, 2017- Novel Agents Improve MCL Care, Tumor Profiling Key to Further AdvancesOctober 21st, 2015
- Join now to see all
Grant Support
- Targeting RAF And VEGF Signaling In Thyroid CancerNational Cancer Institute2005–2006
- Biologic Modifier Therapies In AIDS MalignanciesNational Cancer Institute2002–2004
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
